Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...

Labcorp to serve as the exclusive NOWDiagnostics (NOWDx) distributor for clinical testing in the U.S., offering First to Know® Syphilis Test nationwide BURLINGTON, N.C., Oct 10, 2024 /PRNewswire/ -- ...

BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the ...

As syphilis cases surge nationwide, the collaboration will bring the First To Know ® over-the-counter test to clinicians and patients across professional and hospital settings SPRINGDALE, ...

Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes of cognitive decline for patients 55 years and older. The blood test, which ...

Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...

Consumers Now Have More Choices to Purchase the Visby Device Featuring 30-Minute, Lab-Quality ResultsSAN JOSE, Calif.--(BUSINESS WIRE)--Today, Visby Medical announced two new relationships that will ...